Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Green, A. I. Articles by Schatzberg, A. F. Search for Related Content PubMed Citation Articles by Green, A. I. Articles by Schatzberg, A. F. Bipolar Disorder Other Neuroleptics

Clozapine in the Treatment of Refractory Psychotic Mania

ABSTRACT

OBJECTIVE: The efficacy of clozapine was examined in a group of patients with treatment-refractory bipolar disorder, manic type with psychotic features.METHOD: Twenty-two subjects with treatment-refractory bipolar disorder with active manic and psychotic symptoms participated in a 12-week open-label trial of clozapine. After a 2–10-day drug washout period, patients began treatment with clozapine at 25 mg/day; the dose was increased 25 mg/day (as tolerated) to a maximum level of 550 mg/day. Patients were evaluated longitudinally over the course of the study with the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale, and the Clinical Global Impressions (CGI) scale.RESULTS: Fourteen of the 22 subjects in the study continued taking clozapine for at least 10 of the 12 weeks. Among the entire group, mean improvements of 56.7%, 56.6%, and 39.1% were seen on the BPRS, Young Mania Rating Scale, and CGI, respectively. Seventeen of the 22 subjects (77.3%) experienced at least a 20% improvement in scores on all three scales.CONCLUSIONS: The findings from this open-label study, which are consistent with previous retrospective studies, case reports, and one other open-label prospective study, suggest that clozapine is an effective agent for patients with treatment-refractory psychotic mania.

This article has been cited by other articles:

				A. S. Bassett, E. W.C. Chow, P. AbdelMalik, M. Gheorghiu, J. Husted, and R. Weksberg The Schizophrenia Phenotype in 22q11 Deletion Syndrome Am J Psychiatry, September 1, 2003; 160(9): 1580 - 1586. [Abstract] [Full Text] [PDF]

				R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) Focus, January 1, 2003; 1(1): 64 - 110. [Full Text] [PDF]

				G. S. Sachs, F. Grossman, S. N. Ghaemi, A. Okamoto, and C. L. Bowden Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety Am J Psychiatry, July 1, 2002; 159(7): 1146 - 1154. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us